Carna Biosciences, Inc. (TYO:4572)
214.00
+1.00 (0.47%)
Oct 24, 2025, 3:30 PM JST
Carna Biosciences Revenue
Carna Biosciences had revenue of 107.65M JPY in the quarter ending June 30, 2025, a decrease of -20.26%. This brings the company's revenue in the last twelve months to 572.00M, down -60.28% year-over-year. In the year 2024, Carna Biosciences had annual revenue of 636.00M, down -60.86%.
Revenue (ttm)
572.00M
Revenue Growth
-60.28%
P/S Ratio
7.15
Revenue / Employee
9.08M
Employees
63
Market Cap
4.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 636.00M | -989.00M | -60.86% |
| Dec 31, 2023 | 1.63B | 239.00M | 17.24% |
| Dec 31, 2022 | 1.39B | -631.00M | -31.28% |
| Dec 31, 2021 | 2.02B | 884.00M | 78.02% |
| Dec 31, 2020 | 1.13B | -2.07B | -64.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.48T |
| Otsuka Holdings | 2.40T |
| Astellas Pharma | 1.94T |
| Daiichi Sankyo Company | 1.92T |
| Chugai Pharmaceutical | 1.21T |
| Terumo | 1.04T |
| Olympus | 969.02B |
| HOYA Corporation | 876.09B |